Los Angeles Capital Management LLC Invests $4.19 Million in Catalent, Inc. (NYSE:CTLT)

Los Angeles Capital Management LLC acquired a new position in Catalent, Inc. (NYSE:CTLT) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 93,199 shares of the company’s stock, valued at approximately $4,187,000.

A number of other institutional investors also recently bought and sold shares of the stock. Gladius Capital Management LP purchased a new stake in shares of Catalent in the third quarter worth $28,000. Exchange Traded Concepts LLC purchased a new position in shares of Catalent in the third quarter valued at about $31,000. GAMMA Investing LLC bought a new position in shares of Catalent in the fourth quarter worth about $33,000. Cary Street Partners Investment Advisory LLC grew its position in shares of Catalent by 1,162.3% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock worth $35,000 after purchasing an additional 709 shares in the last quarter. Finally, Rakuten Securities Inc. bought a new stake in Catalent during the 4th quarter valued at approximately $46,000.

Analyst Upgrades and Downgrades

CTLT has been the subject of several recent analyst reports. UBS Group restated a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Barclays raised their target price on shares of Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research note on Thursday, January 25th. Stephens reiterated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Thursday, April 4th. StockNews.com assumed coverage on Catalent in a research report on Sunday. They set a “sell” rating for the company. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research report on Tuesday, February 20th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $52.46.

Catalent Stock Up 0.3 %

Shares of CTLT stock opened at $56.50 on Monday. Catalent, Inc. has a 1 year low of $31.45 and a 1 year high of $60.20. The stock’s 50 day simple moving average is $56.47 and its two-hundred day simple moving average is $49.07. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.73 and a current ratio of 2.48.

Catalent (NYSE:CTLT) last released its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business’s quarterly revenue was down 10.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.62 EPS. Equities research analysts anticipate that Catalent, Inc. will post 0.28 earnings per share for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.